Project title: MECHANICAL, PNEUMATIC AND ULTRASONIC BASED DRUG DELIVERY SYSTEMS

Company name : UBT MEDICAL - ULTIMATE BIO TRANSFER MEDICAL

TRANSFER

TECHNOLOGICAL FIELD
Medical Devices

KEY WORDS
Drug Delivery,
Overactive Bladder, Bladder Cancer

PROJECT SUMMARY
UBT Medical is developing novel mechanical, pneumatic and
ultrasonic -based drug delivery systems, enabling delivery of
required medications into desired targets, to markedly enhance
efficacy and lower overall cost of therapeutic regimens of
urologic chronic diseases or disorders.
The company has identified clinical conditions of significant
market size that lack appropriate solutions. In bladder cancer,
current adjuvant treatment after tumor resection is associated
with poor outcomes due to inadequate penetration into the bladder
wall and excessive patient discomfort due to irritation and pain.
In Overactive Bladder, patients usually suffer from medication
side effects. UBT believes that focused delivery of medication
into the bladder wall will enable better treatment outcomes in
Bladder Cancer, Overactive Bladder and other urological
conditions.

UBT is developing novel, mechanical (KIPOD), ultrasonic (UBSonic)
and pneumatic (UBJet) devices capable of delivering regular or
encapsulated therapeutic agents directly into the bladder wall to
markedly improve intravesical chemotherapy, to reduce the high
rate of bladder cancer recurrence and to improve other bladder
disorder treatments (such as Overactive Bladder).
Being market driven, UBT initially emphasizes the KIPOD solution
which has the combined characteristics of simplicity and high
efficacy, together with short time to market.

The UBT product will consists of a desk-top ultrasound unit, and
a cystoscope-compatible, disposable catheter tipped with
micro-encapsulated chemo agents. The urologist will insert the
catheter into the bladder via a cystoscope and accelerate the
micro-encapsulated agents in the direction of the tumor. Once
embedded in the tumor, the micro-capsules will slowly release the
chemotherapeutic agents over time.

MARKET
Current estimates suggest that overactive bladder may affect
approximately 17% of the adult population in the US and Europe,
which represents 33 million in the US and an estimated 22 million
people in the six main European countries. Bladder cancer is the
fourth leading cause of cancer with high correlation to sex,
smoking and age.
Bladder cancer healthcare costs are $2.2 billion. This is due
primarily to bladder cancer tending to be a lifelong disease,
subject to local recurrence over time, new tumor occurrences in
surrounding areas and progression of disease to more invasive
tumors.

ADVANTAGES
* Enables delivery into the bladder wall
* Enables depth controlled delivery
* Delivers adequate drug concentration
* Drug homogenous dispersion
* Longer exposure of the drug to the tissue
* Utilizes standard urological instruments
* Reduces procedure time
* Lowers treatment costs
* Improves patient's quality of life
* Office procedure
* Fully disposable catheter

ENTREPRENEURS
Prof. Ofer Nativ - Founder & CCO.
Dr. Orit Shaked - Managing
Director
Dr. Alex Melamud - R&D Manager
Dr. Yoni Iger - CSO
Mr. Ronnie Klein - Business
Development Director

PROJECT STATUS
Project began in July 2004. Presently in final development stage
of the KIPOD apparatus and initial development stage of the
pneumatic device (UBJet).

COOPERATION REQUIRED
Investment of US $1.5 million to shorten development period,
complete marketing human trials, and reduce time required for FDA
and CE approval.

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about